Posted by Michael Wonder on 12 Oct 2022
Eylea (aflibercept) injection sBLA for treatment of retinopathy of prematurity accepted for FDA priority review
12 October 2022 - Regeneron Pharmaceuticals today announced the US FDA has accepted for priority review the supplemental biologics license application for Eylea (aflibercept) Injection to treat retinopathy of prematurity in preterm infants.
The target action date for the FDA decision is 11 February 2023.
